



DIAGNÓSTICOS DA AMÉRICA S.A.

A Publicly Held Company
NIRE 35.300.172.507
CNPJ/MF n.º 61.486.650/0001-83

MATERIAL FACT

Diagnósticos da América S.A. (the "Company" or "DASA") reports that it became aware at the date hereof, through notice posted on the site of the Brazilian antitrust authority (the *Conselho Administrativo de Defesa Econômica*, or "CADE"), that this authority, in a judgment session held on July 16, 2014, approved the acquisition by Cromossomo Participações II S/A ("Cromossomo") of common shares issued by the Company, as a result of which Edson de Godoy Bueno and Dulce Pugliese de Godoy Bueno (shareholders owning, indirectly, all of the capital stock of Cromossomo), will control, directly and indirectly, more than 70% of the capital of the Company, pursuant to Act of Concentration 08700.002372/2014-07. CADE's approval was conditioned on complying with an Agreement on Control of Concentrations ("ACC").

The ACC is the equivalent mechanism under current antitrust law (Law 12.529/11), as the old Performance Commitment Instrument applicable under Law 8.884/94.

Furthermore, according to information disclosed by CADE, the ACC obligates Cromossomo's shareholders to formally adhere to the obligations that had been provided for in the Performance Commitment Instrument the Company executed with CADE, in the official papers for Act of Concentration nº 08012.010038/2010-4, which analyzed the association of DASA, MD1 Diagnósticos S.A. and others, as reported in a Material Fact notice disclosed by the Company on December 4, 2013.

The Company has not had access to any information other than that posted by CADE at the following link: <http://www.cade.gov.br/Default.aspx?1427f70110051b18e250e373cf74>

Barueri, July 17, 2014.

Paulo Bokel Catta-Preta
Investor Relations Officer